Concepedia

Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study

Einat Shmueli, Ravit Geva, Nirit Yarom, Ayala Hubert, Rita Keynan, Tal Hetzroni Kedem, Meir Eini, Dov Tamarkin, Mitchell Shirvan

Supportive Care in Cancer · 2019 · 12 citations · 5 references

DOI

Concepts

References

5

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

Mario E. Lacouture, Edith P. Mitchell, Bilal Piperdi et al. · Journal of Clinical Oncology · 2010 · 475 citations

, , +16

Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results

Susan L. Boone, Alfred Rademaker, Dachao Liu et al. · Oncology · 2007 · 188 citations

, , +16

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group

Mario E. Lacouture, Michael L. Maitland, Siegfried Segaert et al. · Supportive Care in Cancer · 2010 · 151 citations

, , +13

Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae.

Lynne I. Wagner, Mario E. Lacouture · PubMed · 2007 · 118 citations

, , +17

A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption

Alon Scope, Jocelyn Lieb, Stephen W. Dusza et al. · Journal of the American Academy of Dermatology · 2009 · 64 citations

, , +10